UY36705A - Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj - Google Patents
Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apjInfo
- Publication number
- UY36705A UY36705A UY0001036705A UY36705A UY36705A UY 36705 A UY36705 A UY 36705A UY 0001036705 A UY0001036705 A UY 0001036705A UY 36705 A UY36705 A UY 36705A UY 36705 A UY36705 A UY 36705A
- Authority
- UY
- Uruguay
- Prior art keywords
- heteroaril
- piridin
- hydroxi
- compounds
- apj agonists
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562170215P | 2015-06-03 | 2015-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY36705A true UY36705A (es) | 2016-11-30 |
Family
ID=56131647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001036705A UY36705A (es) | 2015-06-03 | 2016-06-02 | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj |
Country Status (36)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ737004A (en) | 2015-05-20 | 2022-10-28 | Amgen Inc | Triazole agonists of the apj receptor |
| AR104884A1 (es) | 2015-06-03 | 2017-08-23 | Bristol Myers Squibb Co | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj |
| MX376824B (es) | 2015-10-14 | 2025-03-07 | Bristol Myers Squibb Co | 2,4-dihidroxi-nicotinamidas como agonistas del recepor de apelina (apj). |
| CN108473466B (zh) | 2015-12-04 | 2022-04-19 | 百时美施贵宝公司 | 爱帕琳肽受体激动剂及使用方法 |
| JP6948322B2 (ja) | 2015-12-16 | 2021-10-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ａｐｊ受容体のａｐｊアゴニストとしてのヘテロアリールヒドロキシピリミジノン |
| AU2017238504B2 (en) | 2016-03-24 | 2021-05-27 | Bristol-Myers Squibb Company | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists |
| EP3452466B1 (en) | 2016-05-03 | 2020-08-12 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| ES2844184T3 (es) * | 2016-06-14 | 2021-07-21 | Bristol Myers Squibb Co | 4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ |
| EP3468956B1 (en) | 2016-06-14 | 2021-03-03 | Bristol-Myers Squibb Company | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-ones as apj agonists |
| EP3526198B1 (en) * | 2016-10-14 | 2020-08-12 | Bristol-Myers Squibb Company | 3-sulfonyl-5-aminopyridine-2,4-diol apj agonists |
| MA46827A (fr) | 2016-11-16 | 2019-09-25 | Amgen Inc | Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj |
| EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| WO2018097945A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
| US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
| EP3541810B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| EP3704122B1 (en) | 2017-11-03 | 2021-09-01 | Amgen Inc. | Fused triazole agonists of the apj receptor |
| MA52487A (fr) | 2018-05-01 | 2021-03-10 | Amgen Inc | Pyrimidinones substituées en tant qu'agonistes du récepteur apj |
| CN109704980B (zh) * | 2019-02-16 | 2022-05-13 | 安徽大学 | 一种(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的制备方法 |
| CN109734616B (zh) * | 2019-02-16 | 2022-05-13 | 安徽诺全药业有限公司 | 两步法合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法 |
| CN109704981B (zh) * | 2019-02-16 | 2022-01-28 | 安徽诺全药业有限公司 | 取代合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法 |
| WO2024148104A1 (en) | 2023-01-03 | 2024-07-11 | BioAge Labs, Inc. | Combination therapy of apelin receptor agonist and glp-1 receptor agonist for treating a disease or condition associated with weight gain |
| WO2025213190A1 (en) | 2024-04-05 | 2025-10-09 | BioAge Labs, Inc. | Methods of treating a disease or condition associated with weight gain |
| WO2025251084A1 (en) | 2024-05-31 | 2025-12-04 | BioAge Labs, Inc. | Methods of treating a disease or condition associated with weight gain |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1001159A (en) | 1910-07-25 | 1911-08-22 | Elizabeth Nielsen | Skirt-gage. |
| GB1472257A (en) | 1973-09-10 | 1977-05-04 | Christiaens Sa A | Derivative of 4-hydroxy-5-azacoumarin |
| US4866182A (en) | 1988-02-18 | 1989-09-12 | Merrell Dow Pharmaceuticals Inc. | Cardiotonic alkanoyl and aroyl oxazolones |
| US5338740A (en) | 1993-07-13 | 1994-08-16 | Pfizer Inc. | Angiotensin II receptor antagonists |
| JP3795305B2 (ja) | 1999-07-19 | 2006-07-12 | 田辺製薬株式会社 | 医薬組成物 |
| UA74419C2 (uk) | 2001-02-21 | 2005-12-15 | Ен Пі Ес Фармасьютікалс, Інк. | Заміщені піридини та їх застосування як антагоністів рецептору метаботропного глутамату |
| MXPA03006597A (es) | 2001-03-28 | 2004-10-15 | Pfizer | Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad. |
| US7399759B2 (en) | 2001-09-03 | 2008-07-15 | Takeda Pharmaceutical Company Limited | 1, 3-benzothiazinone derivatives and use thereof |
| JP2005162612A (ja) | 2002-01-09 | 2005-06-23 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| JP2005170790A (ja) | 2002-01-09 | 2005-06-30 | Ajinomoto Co Inc | Ｎ−アルキルスルフォニル置換アミド誘導体 |
| CN100486576C (zh) * | 2002-02-14 | 2009-05-13 | 法玛西雅公司 | 作为p38map激酶调节剂的取代吡啶酮类 |
| US20040147561A1 (en) * | 2002-12-27 | 2004-07-29 | Wenge Zhong | Pyrid-2-one derivatives and methods of use |
| WO2005004818A2 (en) | 2003-07-09 | 2005-01-20 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
| US20060004001A1 (en) | 2004-02-27 | 2006-01-05 | Merz Pharma Gmbh & Co., Kgaa | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors |
| PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
| ATE454372T1 (de) | 2004-04-01 | 2010-01-15 | Lilly Co Eli | Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen |
| WO2006002099A2 (en) | 2004-06-18 | 2006-01-05 | Millennium Pharmaceuticals, Inc. | Factor xa inhibitors |
| EP1786790B1 (en) | 2004-07-26 | 2009-06-03 | Eli Lilly And Company | Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses |
| EP1655283A1 (en) | 2004-11-08 | 2006-05-10 | Evotec OAI AG | 11beta-HSD1 Inhibitors |
| WO2006123165A2 (en) * | 2005-05-19 | 2006-11-23 | Astex Therapeutics Limited | Pyrimidine derivatives as hsp90 inhibitors |
| WO2007023242A1 (en) | 2005-08-24 | 2007-03-01 | Merz Pharma Gmbh & Co. Kgaa | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors |
| EP1984353B1 (en) | 2006-01-23 | 2015-12-30 | Amgen, Inc | Aurora kinase modulators and method of use |
| JP2007314516A (ja) | 2006-04-25 | 2007-12-06 | Daiichi Sankyo Co Ltd | ２以上の置換基を有するベンゼン化合物を含有する医薬 |
| BRPI0714793A2 (pt) | 2006-08-03 | 2015-06-16 | Tufts College | Análogos de niacina não enrubecedores e método de uso dos mesmos. |
| US20090318389A1 (en) | 2006-08-04 | 2009-12-24 | Praecis Pharmaceuticals Incorporated | Agonists of the sphingosine-1 phosphate receptor |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| KR20090087019A (ko) | 2006-12-01 | 2009-08-14 | 노파르티스 아게 | 생리적 심비대의 촉진을 위한 단백질 티로신 포스파타제의 억제제 |
| MX2009010122A (es) | 2007-03-28 | 2009-10-19 | Neurosearch As | Derivados de purinilo y su uso como moduladores del canal de potasio. |
| CN102026970B (zh) * | 2007-11-21 | 2013-07-31 | 解码遗传Ehf公司 | 用于治疗肺部和心血管病症的联芳基pde4抑制剂 |
| BRPI0907650A2 (pt) | 2008-01-25 | 2015-07-21 | Torrent Pharmaceuticals Ltd | Composições farmacêuticas compreendendo degradadores de produtos finais de glicosilação avançada (ages) e drogas adjuvantes como drogas anti-hipertensivas, antidiabéticas e etc |
| AU2009233711B2 (en) | 2008-04-09 | 2015-02-12 | Infinity Pharmaceuticals, Inc | Inhibitors of fatty acid amide hydrolase |
| JP2011523997A (ja) | 2008-05-30 | 2011-08-25 | フォスター ホイーラー エナージア オサケ ユキチュア | 酸素燃焼によって動力を発生させるための方法及び装置 |
| JP2011526917A (ja) | 2008-06-30 | 2011-10-20 | サイレーン ファーマシューティカルズ， インコーポレイテッド | オキシインドール化合物 |
| JP5535931B2 (ja) | 2008-10-27 | 2014-07-02 | 武田薬品工業株式会社 | 二環性化合物 |
| AU2009311640B2 (en) * | 2008-11-04 | 2013-09-26 | Anchor Therapeutics, Inc. | APJ receptor compounds |
| CA2771026A1 (en) | 2009-09-24 | 2011-03-31 | F. Hoffmann-La Roche Ag | Indole derivatives as crac modulators |
| CN102510864A (zh) | 2009-09-24 | 2012-06-20 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒杂环化合物 |
| WO2011062955A2 (en) | 2009-11-18 | 2011-05-26 | University Of Massachusetts | Compounds for modulating tlr2 |
| CA2783801A1 (en) | 2009-12-18 | 2011-06-23 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| CN102241621A (zh) | 2010-05-11 | 2011-11-16 | 江苏恒瑞医药股份有限公司 | 5,5-双取代-2-亚氨基吡咯烷类衍生物、其制备方法及其在医药上的应用 |
| CN102906074A (zh) | 2010-05-24 | 2013-01-30 | 东亚荣养株式会社 | 稠合咪唑衍生物 |
| EP2619190B1 (en) * | 2010-09-24 | 2015-08-12 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| WO2012074022A1 (ja) | 2010-12-01 | 2012-06-07 | 旭硝子株式会社 | イリジウムカチオン錯体および発光組成物 |
| US20140057953A1 (en) | 2011-03-03 | 2014-02-27 | Rolf Hartmann | Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors |
| EP2697196A1 (en) | 2011-04-13 | 2014-02-19 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| WO2012158844A1 (en) | 2011-05-17 | 2012-11-22 | Shionogi & Co., Ltd. | Heterocyclic compounds |
| CN104169278B (zh) | 2011-12-23 | 2017-10-24 | 巴斯夫欧洲公司 | 防治无脊椎动物害虫的异噻唑啉化合物 |
| US9399638B2 (en) * | 2012-05-02 | 2016-07-26 | Lupin Limited | Substituted pyridine compounds as CRAC modulators |
| WO2013167633A1 (en) | 2012-05-09 | 2013-11-14 | Basf Se | Acrylamide compounds for combating invertebrate pests |
| US9359284B2 (en) | 2012-06-08 | 2016-06-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | Benzathine analogs |
| EP2866803A1 (en) | 2012-07-02 | 2015-05-06 | Max-Delbrück-Centrum für Molekulare Medizin Berlin-Buch | Psoralen derivatives for preventing or treating heart failure or cardiac hypertrophy |
| CN103570625A (zh) | 2012-07-19 | 2014-02-12 | 南京英派药业有限公司 | N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用 |
| WO2014031928A2 (en) | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
| CN104640846A (zh) * | 2012-09-21 | 2015-05-20 | 赛诺菲 | 用作apj受体调节剂的苯并咪唑-羧酸酰胺衍生物 |
| WO2014062938A1 (en) | 2012-10-19 | 2014-04-24 | Bristol-Myers Squibb Company | Rory modulators |
| EP2972394A4 (en) | 2013-03-15 | 2016-11-02 | Sloan Kettering Inst Cancer | HSP90-DESIGNING AND THERAPY |
| EP3027625B1 (en) | 2013-07-31 | 2018-05-30 | Merck Sharp & Dohme Corp. | Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure |
| JP6199197B2 (ja) | 2014-02-07 | 2017-09-20 | 花王株式会社 | ポリオキシアルキレンアルキルエーテルカルボン酸塩の製造方法 |
| JP2017071553A (ja) | 2014-02-25 | 2017-04-13 | 味の素株式会社 | ヘテロ原子−メチレン−ヘテロ環構造を有する新規化合物 |
| MX2016012175A (es) | 2014-03-20 | 2017-01-19 | Bayer Pharma AG | Nuevos compuestos. |
| CA2950952C (en) | 2014-06-10 | 2023-01-10 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof |
| NZ737004A (en) | 2015-05-20 | 2022-10-28 | Amgen Inc | Triazole agonists of the apj receptor |
| AR104884A1 (es) | 2015-06-03 | 2017-08-23 | Bristol Myers Squibb Co | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj |
| KR101711744B1 (ko) | 2015-07-16 | 2017-03-02 | 경희대학교 산학협력단 | 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층 |
| MX376824B (es) | 2015-10-14 | 2025-03-07 | Bristol Myers Squibb Co | 2,4-dihidroxi-nicotinamidas como agonistas del recepor de apelina (apj). |
| EP3380970B1 (en) | 2015-11-24 | 2023-01-04 | Sanford Burnham Prebys Medical Discovery Institute | Novel azole derivatives as apelin receptor agonist |
| CN108473466B (zh) | 2015-12-04 | 2022-04-19 | 百时美施贵宝公司 | 爱帕琳肽受体激动剂及使用方法 |
| WO2017100558A1 (en) | 2015-12-09 | 2017-06-15 | Research Triangle Institute | Improved apelin receptor (apj) agonists and uses thereof |
| JP6948322B2 (ja) | 2015-12-16 | 2021-10-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ａｐｊ受容体のａｐｊアゴニストとしてのヘテロアリールヒドロキシピリミジノン |
| AU2017238504B2 (en) | 2016-03-24 | 2021-05-27 | Bristol-Myers Squibb Company | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists |
| ES2844184T3 (es) | 2016-06-14 | 2021-07-21 | Bristol Myers Squibb Co | 4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ |
| EP3468956B1 (en) | 2016-06-14 | 2021-03-03 | Bristol-Myers Squibb Company | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-ones as apj agonists |
| EP3526198B1 (en) | 2016-10-14 | 2020-08-12 | Bristol-Myers Squibb Company | 3-sulfonyl-5-aminopyridine-2,4-diol apj agonists |
-
2016
- 2016-06-02 AR ARP160101639A patent/AR104884A1/es unknown
- 2016-06-02 PT PT16729454T patent/PT3303330T/pt unknown
- 2016-06-02 MX MX2017014956A patent/MX378998B/es unknown
- 2016-06-02 WO PCT/US2016/035482 patent/WO2016196771A1/en not_active Ceased
- 2016-06-02 SM SM20190427T patent/SMT201900427T1/it unknown
- 2016-06-02 HU HUE16729454A patent/HUE045546T2/hu unknown
- 2016-06-02 EP EP19168724.3A patent/EP3530660A1/en not_active Withdrawn
- 2016-06-02 HR HRP20191327 patent/HRP20191327T1/hr unknown
- 2016-06-02 RS RSP20190961 patent/RS59220B1/sr unknown
- 2016-06-02 PE PE2017002482A patent/PE20180506A1/es unknown
- 2016-06-02 HK HK18107278.8A patent/HK1247915B/en unknown
- 2016-06-02 SI SI201630316T patent/SI3303330T1/sl unknown
- 2016-06-02 MA MA41562A patent/MA41562B1/fr unknown
- 2016-06-02 KR KR1020177037657A patent/KR102066336B1/ko active Active
- 2016-06-02 CN CN201680045336.7A patent/CN107922401B/zh active Active
- 2016-06-02 TN TNP/2017/000503A patent/TN2017000503A1/en unknown
- 2016-06-02 MY MYPI2017704612A patent/MY189453A/en unknown
- 2016-06-02 NZ NZ73856316A patent/NZ738563A/en unknown
- 2016-06-02 UY UY0001036705A patent/UY36705A/es unknown
- 2016-06-02 LT LTEP16729454.5T patent/LT3303330T/lt unknown
- 2016-06-02 TW TW105117468A patent/TWI672299B/zh active
- 2016-06-02 JP JP2017562603A patent/JP6483288B2/ja active Active
- 2016-06-02 PH PH1/2017/502158A patent/PH12017502158B1/en unknown
- 2016-06-02 EP EP16729454.5A patent/EP3303330B1/en active Active
- 2016-06-02 PL PL16729454T patent/PL3303330T3/pl unknown
- 2016-06-02 AU AU2016270903A patent/AU2016270903B2/en active Active
- 2016-06-02 ME MEP-2019-211A patent/ME03474B/me unknown
- 2016-06-02 DK DK16729454.5T patent/DK3303330T3/da active
- 2016-06-02 US US15/171,276 patent/US10011594B2/en active Active
- 2016-06-02 ES ES16729454T patent/ES2739526T3/es active Active
- 2016-06-02 EA EA201792548A patent/EA034912B1/ru not_active IP Right Cessation
- 2016-06-02 CA CA2988147A patent/CA2988147C/en active Active
-
2017
- 2017-11-27 IL IL255951A patent/IL255951B/en active IP Right Grant
- 2017-11-30 CL CL2017003055A patent/CL2017003055A1/es unknown
- 2017-12-01 ZA ZA2017/08191A patent/ZA201708191B/en unknown
- 2017-12-21 CO CONC2017/0013229A patent/CO2017013229A2/es unknown
-
2018
- 2018-05-29 US US15/990,855 patent/US10336739B2/en active Active
-
2019
- 2019-02-13 JP JP2019023478A patent/JP2019094345A/ja active Pending
- 2019-05-14 US US16/411,221 patent/US20190263791A1/en not_active Abandoned
- 2019-07-29 CY CY20191100803T patent/CY1121938T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY36705A (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| CO2018006662A2 (es) | Agonistas del receptor de apelina y métodos de uso | |
| CO2018004968A2 (es) | 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) | |
| CO2018007221A2 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj) | |
| CO2018011105A2 (es) | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj) | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2017002122A1 (es) | Heterociclos bicíclicos como inhibidores de fgfr4 | |
| CL2017002483A1 (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
| UY35908A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| MX2018007390A (es) | Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo. | |
| DOP2016000211A (es) | Pirazinas moduladoras de gpr6 | |
| CR20150417A (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| BR112016028948A2 (pt) | ?composição bifásica? |